Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer von Marín-Aguilera, M., Jares, P., Sanfeliu, E., Villacampa, G., Hernández-lllán, E., Martínez-Puchol, A.I., Shankar, S., González-Farré, B., Waks, A.G., Brasó-Maristany, F., Pardo, F., Manning, D.K., Abery, J.A., Curaba, J., Moon, L., Gordon, O., Galván, P., Wachirakantapong, P., Castillo, O., Nee, C.M., Blasco, P., Senevirathne, T.H., Sirenko, V., Martínez-Sáez, O., Aguirre, A., Krop, I.E., Li, Z., Spellman, P., Metzger Filho, O., Polyak, K., Michaels, P., Puig-Butillé, J.A., Vivancos, A., Matito, J., Buckingham, W., Perou, C.M., Villagrasa-González, P., Prat, A., Parker, J.S., Paré, L.

Volltext

140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analy... von Guarneri, V., Dieci, M.V., Griguolo, G., Pare Brunet, L., Marin, M., Miglietta, F., Bottosso, M., Giorgi, C.A., Blasco, P., Castillo, O., Galván, P., Jares, P., Puig-butille, J.A., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Conte, P.F., Prat, A.

Volltext

268P Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence von Angelats, L., Brunet, L. Pare, Rubio-Perez, C., Torres, E. Sanfeliu, Solis, E. Segui, Villacampa, G., Marin, M., Conte, B., Saez, O. Martinez, Fernandez-Martinez, A., Buckingham, W., Guedan, S., Heyn, H., Vivancos, A., Parker, J., Gonzalez, P. Villagrasa, Perou, C.M., Prat, A., Maristany, F. Braso

Volltext

280P Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making von Céspedes, M. Tapia, Cussac, A. Llombart, Tebar, C., Liebana, S.M., Molina, A. Magro, Abad, L. Palomar, Martinez, M.T.M., Melia, C. Hernando, Iranzo, V., Pouptsis, A., Bertran, A. Santaballa, Torregrosa Maicas, M.D., Burgués, O., Cano, I. Garrido, Lluch-Hernandez, A., Gonzalez, P. Villagrasa, Prat, A., bermejo, B., Cejalvo, J.M.

Volltext

153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC) von Conte, P.F., Pare Brunet, L., Brasó-Maristany, F., Chic, N., Martinez Saez, O., Dieci, M.V., Marin, M., Guarneri, V., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Prat, A.

Volltext

25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial von Brasó-Maristany, F., Martinez Saez, O., Pare Brunet, L., Marín-Aguilera, M., Conte, P.F., Jares, P., Guarneri, V., Pascual, T., Puig-Butille, J.A., Vivancos, A., Parker, J., Villagrasa Gonzalez, P., Tolaney, S.M., Carey, L.A., Perou, C.M., Prat, A.

Volltext

150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial von Llombart Cussac, A., Pérez-García, J.M., Pare Brunet, L., Villacampa Javierre, G., Brasó-Maristany, F., Gion Cortes, M., Schmid, P., Colleoni, M.A., Ruiz Borrego, M., Galván, P., Parker, J., Perou, C.M., Villagrasa Gonzalez, P., Guerrero, J.A., Sampayo-Cordero, M., Mancino, M., Prat, A., Cortés, J.

Volltext

149P Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the ne... von Gomez Serra, N., Brasó-Maristany, F., Fullana Grimalt, B., Ortega, R., Petit, A., Vicente, M., Falo, C., Stradella, A., Bañuls, M., Pare Brunet, L., Marín-Aguilera, M., Fernandez Ortega, A., Vethencourt, A., Cordero, D., Iserte, A., Galván, P., Perou, C.M., Villagrasa Gonzalez, P., Prat, A., Pernas Simon, S.

Volltext

3MO Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC) von Conte, B., Brasó-Maristany, F., Pascual, T., Schettini, F., Staaf, J., Paré, L., Marín-Aguilera, M., Martínez-Sáez, O., Rodriguez Hernandez, A., Vidal Losada, M.J., Conte, P.F., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Prat, A.

Volltext

237P HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1 von Brasó-Maristany, F., Griguolo, G., Chic, N., Pare Brunet, L., Galván, P., Dieci, M.V., Miglietta, F., Giarratano, T., Martínez-Sáez, O., Marin, M., Vidal Losada, M.J., Adamo, B., Munoz, M., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Conte, P.F., Prat, A., Guarneri, V.

Volltext

208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positiv... von Ciruelos, E.M., Ponce, J., Pernas Simon, S., Cortés, J., Cantos, B., Garate, E., Vega Alonso, E., Mele Olive, M., Martinez De Dueñas, E., Montaño Perianez, A., Martinez, N., Perello Martorell, A., Bermejo De Las Heras, B., Arqueros Nunez, C., Fernández, I., De la Haba Rodriguez, J., Oliveira, M., González, X., Villagrasa Gonzalez, P., Prat, A.

Volltext

119PERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therap... von Chic, N, Pascual, T, Brasó-Maristany, F, Villagrasa Gonzalez, P, Pare Brunet, L, Schettini, F, Conte, B, Adamo, B, Vidal, M, Muñoz, M, Martínez, O, Gonzalez-Farre, B, Cortés, J, Llombart-Cussac, A, Rodrik-Outmezguine, V, Izquierdo Delso, M A, Schiff, R, Osborne, C K, Rimawi, M, Prat, A

Volltext

ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (E... von Chic, N., Pascual, T., Brasó-Maristany, F., Villagrasa Gonzalez, P., Pare Brunet, L., Schettini, F., Conte, B., Adamo, B., Vidal, M., Muñoz, M., Martínez, O., Gonzalez-Farre, B., Cortés, J., Llombart-Cussac, A., Rodrik-Outmezguine, V., Izquierdo Delso, M.A., Schiff, R., Osborne, C.K., Rimawi, M., Prat, A.

Volltext

119P - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine the... von Chic, N., Pascual, T., Brasó-Maristany, F., Villagrasa Gonzalez, P., Pare Brunet, L., Schettini, F., Conte, B., Adamo, B., Vidal, M., Muñoz, M., Martínez, O., Gonzalez-Farre, B., Cortés, J., Llombart-Cussac, A., Rodrik-Outmezguine, V., Izquierdo Delso, M.A., Schiff, R., Osborne, C.K., Rimawi, M., Prat, A.

Volltext

49P A ctDNA tool for identifying ESR1-mutated biology in ESR1-non-mutated hormone receptor-positive (HR+) metastatic breast cancer (MBC) von Fructuoso, I. Garcia, Martínez-Sáez, O., Pardo, F., Vega León, M.D.R., Matito, J., Brunet, L. Pare, Castillo, O., Javierre, G. Villacampa, Galván, P., Odegaard, J., Gonzalez, P. Villagrasa, Parker, J., Perou, C.M., Vivancos, A., Prat, A., Brasó-Maristany, F.

Volltext

6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials von Tarantino, P., Villacampa, G., Graham, N., Waks, A.G., Gonzalez, P. Villagrasa, Brasó-Maristany, F., Torres, E. Sanfeliu, Galván, P., Brunet, L. Pare, Demeo, M.K., Partridge, A.H., Burstein, H.J., Krop, I., Tayob, N., Winer, E.P., Prat, A., Tolaney, S.M.

Volltext

1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer von Javierre, G. Villacampa, Cortés, J., García, J.M. Pérez, Cussac, A. Llombart, Tarantino, P., Conte, P.F., Mancino, M., Guarneri, V., Dieci, M.V., Waks, A., Brasó-Maristany, F., Pascual, T., Griguolo, G., Gonzalez, P. Villagrasa, Parker, J., Vivancos, A., Perou, C.M., Brunet, L. Pare, Prat, A., Tolaney, S.M.

Volltext

13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratification von Bayona, R. Sanchez, Martínez-Sáez, O., Romero, D.R., Solis, E. Segui, Carcelero, E., Ortega, P. Tolosa, García, J. Soberino, Bianchi, M. Alva, Pascual, T., Gaspar, A.M., Javierre, G. Villacampa, Buckingham, W., Marin, M., Brunet, L. Pare, Gonzalez, P. Villagrasa, Perou, C.M., Maues, J., Prat, A., Brasó-Maristany, F., Ciruelos, E.M.

Volltext

14P Assessing the predictive value of HER2DX pCR-score for pathologic complete response (pCR) in early-stage HER2-positive (HER2+) breast cancer (BC) under real-world conditions von Martínez-Sáez, O., Marin, M., Brunet, L. Pare, Javierre, G. Villacampa, Vivancos, A., Losada, M.J. Vidal, Adamo, B., Bravo, R. Gómez, Fructuoso, I. Garcia, Pascual, T., Chic, N., Rivera, P.R., Schettini, F., Solís, E. Seguí, Conte, B., Gonzalez, P. Villagrasa, Torres, E. Sanfeliu, Brasó-Maristany, F., Prat, A., Munoz, M.

Volltext

8P Evaluating HER2DX pCR-Score and MRI response in predicting pathologic complete response (pCR) to anti-HER2 neoadjuvant chemotherapy (CT) in early-stage HER2-positive (HER2+) bre... von Pascual, T., Martínez-Sáez, O., Brunet, L. Pare, Javierre, G. Villacampa, Vivancos, A., Bargalló, X., Ganau, S., Úbeda, B., Sitges, C., Losada, M.J. Vidal, Adamo, B., Gomez-Bravo, R., García-Fructuoso, I., Schettini, F., Solis, E. Segui, Conte, B., Gonzalez, P. Villagrasa, Torres, E. Sanfeliu, Prat, A., Brasó-Maristany, F.

Volltext